Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of rFVIIIFc (BIIB031) in pediatric hemophilia A
2011-003073-28Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efmoroctocog alfa in hemophilia A, sponsored by Biogen. Primary endpoint: Inhibitor development. Started May 2012; status: completed.
02
Drugs
efmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2011-003073-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003073-28.